Compound News and Research

RSS

Can supplements slow Parkinson’s disease? Review reveals where the evidence stands

Dietary supplements are widely used by people with Parkinson’s disease, but this review finds that none have yet been proven to slow disease progression. Biotics, nicotinamide riboside, and omega-3 fatty acids combined with vitamin E show the most promise, but larger, longer, and better-designed trials are needed.

14 May 2026

Scientists develop a dual action strategy to destabilize the COVID virus

An unprecedented study led by researchers at the University of Malaga proposes a new antiviral strategy against SARS-CoV-2 -the virus responsible for causing COVID-19 disease- based on a treatment that combines two complementary approaches, capable of attacking the virus simultaneously, forcing its instability and hindering its ability to adapt.

14 May 2026

Rhein protects against intestinal injury in severe acute pancreatitis

Severe acute pancreatitis (SAP) remains one of the most formidable challenges in gastrointestinal emergency medicine.

13 May 2026

New compound shows promise as single-dose malaria treatment

A Portland State University-led research team has developed a novel chemical compound that shows promise for the treatment and prevention of malaria, one of the world's deadliest diseases.

13 May 2026

Dual-pathway protein degradation approach could improve cancer treatment

Targeted protein degradation has become one of the most promising strategies in modern drug discovery, enabling scientists to eliminate disease-causing proteins instead of merely blocking them.

12 May 2026

INDIGO Biosciences expands reporter assay capabilities with new Transrepression Assay Services

INDIGO Biosciences today announced the launch of its Transrepression Assay Services, expanding the company’s cell-based reporter assay capabilities for drug discovery teams studying pathway cross-talk, selective modulation, and transcription factor-mediated gene suppression.

From INDIGO Biosciences, Inc. 11 May 2026

Yale study finds garlic acts as birth control for mosquitoes

Garlic is not a substance that most people consider an aphrodisiac. It turns out that mosquitoes agree.

11 May 2026

Garlic-derived compound may help improve muscle strength during aging

Can a compound derived from a common kitchen ingredient help support muscle health during aging? A new study suggests it can.

7 May 2026

A new combined therapy to boost the immune system against cancer

Cancer immunotherapy is built on a simple but powerful idea: the immune system can recognize and destroy cancer cells if it is properly activated. In many patients, however, this response is too weak or too slow to be effective.

7 May 2026

Artificial intelligence accelerates discovery of next-generation disinfectants

Chemists and computer scientists tapped AI to find new disinfectants to combat the growing threat of dangerous "superbugs."

5 May 2026

Single psilocybin dose linked to lasting brain and mood changes

Researchers at UC San Francisco and Imperial College London have shown that a single dose of psilocybin, the psychedelic compound found in magic mushrooms, causes likely anatomical brain changes that last for up to a month after the experience.

5 May 2026

Machine learning study identifies distinct subtypes of Parkinson's disease

A new study led by researchers from VIB and KU Leuven shows that Parkinson's disease can be divided into distinct subtypes, helping explain why a single treatment does not work for all patients.

5 May 2026

New molecular framework paves the way for targeted Parkinson’s therapeutic interventions

A new study led by researchers from VIB and KU Leuven shows that Parkinson's disease can be divided into distinct subtypes, helping explain why a single treatment does not work for all patients. Using an machine-learning-driven analysis, the team identified two main groups and five subgroups of the disease, marking an important step toward more personalized therapies. The findings were recently published in Nature Communications.

5 May 2026

NIH awards $3.9 million grant to develop a non-opioid pain treatment

The National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health (NIH), has awarded a $3.9 million grant to a multi-institutional team led by scientists at Sanford Burnham Prebys Medical Discovery Institute to develop a non-opioid pain therapeutic and advance it into a Phase 1 clinical trial.

4 May 2026

Finding new ways to mimic ketamine’s antidepressant effects

Weill Cornell Medicine investigators have "reverse engineered" ketamine's antidepressant effects to identify potential new strategies for treating depression.

4 May 2026

Study debunks steroid myths, framing creatine as an essential energy-providing molecule

Creatine, a compound often associated with gym-goers and athletes, has long been touted as a performance-enhancing supplement. But beyond the hype, what does science actually reveal about its effects on the body and mind?

4 May 2026

Five-target drug beats GLP-1/GIP therapy in obese diabetic mice

A Nature study reports a single-molecule GLP-1–GIP–lanifibranor quintuple agonist that targets incretin receptor-expressing cells while activating PPARα/γ/δ pathways. In obese and insulin-resistant mice, the compound reduced body weight, food intake, and hyperglycaemia more effectively than semaglutide or GLP-1R–GIPR co-agonism, while remaining a preclinical finding.

30 Apr 2026

Climate change increases stroke risk through extreme weather and pollution

The World Stroke Organization is warning that climate change poses an escalating threat to brain health, with extreme heat in particular increasing the risk of having a stroke and of patients dying from stroke.

30 Apr 2026

Sapio Sciences brings Claude Cowork to the lab

Sapio Sciences, the AI lab informatics company, today announced that Claude Cowork, Anthropic's agentic AI assistant, is now integrated with the Sapio Platform via Sapio Elain, the AI co-scientist.

From Sapio Sciences 30 Apr 2026

New AI models quickly find compounds that target Lyme bacteria

Tufts University researchers are using AI and machine learning to more quickly identify potential narrow-spectrum antibiotics to prevent and treat Lyme disease, thanks to a generous gift from an alumnus that sped up their timeline by two to three years.

28 Apr 2026